RT Journal Article
SR Electronic
T1 278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A318
OP A319
DO 10.1136/jitc-2023-SITC2023.0278
VO 11
IS Suppl 1
A1 Lam, Viola C
A1 Li, Aileen
A1 Casas, Meritxell Galindo
A1 Barragan, Jessica
A1 Cheung, Christina
A1 Briones, Jessica
A1 Afreen, Esha
A1 Vavra, Grant
A1 Lu, Jia
A1 Sundar, Purnima
A1 Martinez, Rowena
A1 Sims, Candace
A1 Ta, Christina
A1 Nigatu, Eskedar
A1 Potluri, Shobha
A1 Ali, Omar
A1 Cheung, Alexander S
A1 Lynn, Rachel C
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A318.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.